Endocrinology Flashcards
Where is insulin secreted?
Pancreatic beta cells (islets of Langerhans)
What is the action of insulin? (2)
To increase cellular uptake of glucose, fatty acids and amino acids into the liver, adipose tissue and muscle.
Also promotes storage of nutrients in the form of glycogen, lipids and protein respectively.
Describe the synthesis of insulin (3)
Synthesised form precursor (proinsulin).
Proinsulin is cleaved by the endoplasmic reticulum into active form insulin and a C peptide fragment.
Both are stored in secretory granules in beta cells awaiting release by exocytosis.
What receptor (promoted by insulin) promotes glucose uptake on the cell surface of muscle and adipose tissue cells?
GLUT4
Describe 4 types of glucose transporter proteins. Which is the most common?
GLUT-1 - Allows basal non-insulin stimulated glucose uptake into cells.
GLUT-2 - Transports glucose into beta cells, allowing them to sense serum glucose concentrations (low affinity receptor - so require high conc of glucose)
GLUT-3 - Enables non-insulin mediated uptake of glucose into brain, neurones and placents
GLUT-4 - Mediates majority of peripheral action of insulin, promoting glucose uptake into muscle and adipose tissue (most common)
Where is the majority of insulin extracted and degraded?
In the liver (50%)
Define gluconeogenesis
Glucose synthesis
Describe the impact of insulin on the liver
Acts on hepatocytes to inhibit gluconeogenesis (glucose synthesis) and activate glycogenesis (formation of glycogen), resulting in glycogen storage within the liver.
Define glycogenesis
Glycogen synthesis
Define glycogenolysis
Glycogen breakdown
Describe the impact of insulin on muscle (3)
Post-prandial spike (after eating) in insulin acts on monocytes to increase glucose import and shifts muscle metabolism to primarily use glucose as an energy source.
Promotes amino acid import and protein synthesis in muscle and inhibits protein degeneration and metabolism.
Promotes potassium uptake into cells, thus preventing dangerous hyperkalaemia following a meal.
Describe glycogen
Mainly stored in liver and muscles. Accumulated in response to insulin and broken down into glucose by glucagon
What hormone is released in response to low glucose levels? Where is it released?
Glucagon.
Released by pancreatic alpha cells
Describe glucagon
Peptide hormone produced by alpha cells of the pancreas.
Increase concentration of blood glucose (counteracts insulin) by stimulating hepatic glucose production through the breakdown of glycogen.
Describe the function of glucagon and where it acts. (3)
Acts on the liver to;
Convert glycogen to glucose (glycogenolysis)
Forms glucose from lactic acid and amino acids (gluconeogenesis)
Stimulates lipolysis and muscle glycogenolysis and breakdown (increased ketogenesis)
What are normal blood glucose levels?
3.5-8.00 mmol/L
Define diabetes mellitus (2)
Describes a reduced responsiveness to endogenous insulin.
Described as a syndrome of chronic hyperglycaemia due to relative insulin deficiency, resistance or both
Describe the difference between type 1 and type 2 diabetes
Type 1 - An inability to synthesise insulin
Type 2 - The body becoming resistant to the effects of insulin.
Name 3 microvascular complications of diabetes
Retinopathy (blurred vision, cotton wool sports, macular oedema)
Neuropathy (pain - at night, numbness in feet and hands, paraesthesia)
Nephropathy (microalbuminuria)
Name 3 macrovascular complications of diabetes
Stroke
MI
Limb ischaemia
Give 4 secondary causes of diabetes
Pancreatic pathology (total pancreatectomy, chronic pancreatitis, haemochromatosis)
Endocrine disease (acromegaly, cushing’s disease, hyperthyroidism)
Drug induces (thiazide diuretics, corticosteroids)
Maturity onset diabetes of youth (MODY)
Define MODY. When does it present? (3)
Maturity onset diabetes of youth (MODY)
Describes an autosomal dominant form of type 2 diabetes.
Presents in <25 year olds with a positive family history.
Describe 3 types of MODY
MODY1 - Mutation in HNF4A (presents in neonates - macrosomia and hyperglycaemia)
MODY2 - Mutation in GCK (glycokinase - sensor of pancreatic b-cells)
MODY3 - Mutation in HNF1A (patients respond well to sulfonylurea treatment so don’t require insulin)
Define type 1 diabetes
Describes a disease of insulin deficiency caused by the autoimmune destruction of insulin producing pancreatic beta cells.
Mutations in which HLA genes are strongly linked to type 1 diabetes? (2)
HLA-DR3 and HLA-DR4
Name 4 autoantibodies involved in type 1 diabetes
Anti-GAD (most common)
Pancreatic islet cell Ab
Islet antigen 1Ab
ZnT8 (zinc transporter 8)
When is the peak incidence of type 1 diabetes?
Manifests during childhood, peak incidence around puberty)
<30 years old and tend to be lean
Give 4 risk factors for Type 1 Diabetes
Family history (HLA-DR3/DR4)
Autoimmune disease (autoimmune thyroid, coeliac disease, addison’s disease, pernicious anaemia)
Environmental factors (diet, coxsackie B4, vitamin D deficiency)
Describe the pathophysiology of type 1 diabetes
Autoimmune destruction of insulin producing beta cells > insulin deficiency > glucose cannot be taken up by cells > body resultantly responds as if were hypoglucaemic > liver compensates by increasing glycogenolysis (producing glucose and ketones) > glucose is excreted by kidney leading to glycosuria and ketouria > increase in glucose and ketone excretion pulls more water into urine leading to thirst and polyuria.
Describe symptom triad of type 1 diabetes (3)
Polyuria/nocturia
Polydipsia (thirst)
Weight loss
Give 3 additional clinical signs of type 1 diabetes
Early onset (childhood/adolescence)
Lead body physique/build
Acute onset of osmotic symptoms (polyuria/nocturia/polydipsia/weight-loss)
Name 3 additional presenting features of type 1 diabetes
Hunger (hyperphagia - due to lack of usable energy source i.e glucose)
Pruritis vulvae and balanitis (glucosuria increases infection risk)
Blurred vision (lens swelling due to increased uptake of glucose and water)
Give 6 investigations used to diagnose type 1 diabetes
Urine dipstick for glucose and ketones
Random plasma glucose (>11mmol/L - confirms diagnosis)
Fasting plasma glucose (>7mmol/L)
Oral glucose tolerance test (>11mmol/L)
Autoimmune markers (i.e Anti-GAD)
Fasting C-peptide (Byproduct of insulin generation - Low due to absence of insulin secretion)
Describe the diagnostic criteria for a symptomatic patient with ? Type 1 diabetes
Fasting plasma glucose >7mmol/L
Random plasma glucose >11mmol/L (or after 75g oral glucose tolerance test)
Describe the diagnostic criteria for an asymptomatic patient with ? type 1 diabetes
Fasting plasma glucose >7mmol/L
Random plasma glucose >11mmol/L (or after 75g oral glucose tolerance test)
ON TWO SEPERATE OCCASIONS
What is more common Type 1 Diabetes or Type 2?
Type 2 diabetes
Describe 5 differences between type 1 and type 2 diabetes
Age of onset - Type 1 <20 years, Type 2 >40 years
Speed of onset - Type 1 more acute (hours/days), Type 2 slower (weeks/months)
Weight of patient - Type 1 recent weight loss typical, Type 2 Obesity strong risk factor
Features - Type 1 features of DKA, Type 2 milder symptoms (polyuria, polydipsia)
Ketonuria - Type 1 common, Type 2 rare.
NICE recommend diagnosis Type 1 diabetes on clinical grounds in adults presenting with hyperglycaemia, bearing in mind that Type 1 diabetics also have one or more what features? (5)
One or more of;
Ketosis
Rapid weight loss
Age of onset <50 years
BMI below 25kg/m2
Personal and/or family history of autoimmune disease
What further test is recommended by NICE to diagnose Type 1 Diabetes?
Measurement of C-peptide and/or diabetes specific antibodies
How is type 1 diabetes managed? (4)
Multiple daily subcutaneous insulin injections
Monitor HbA1c every 3-6 months (target of >48mmol/L in adults)
Self-monitor blood glucose 4 times a day (before each meal and before bed)
Metformin (if BMI is >25kg/m2)
Describe the blood glucose targets for those being managed for type 1 diabetes
5-7mmol/L on waking AND 4-7mmol/L before meals at other times of the day
What complications can occur as a result of insulin treatment? And how can these be prevented?
Hyperglycaemia (due to not taking enough insulin)
Hypoglycaemia (due to taking too much)
Can use DAFNE (Dose Adjusted for Normal Eating) - Teaches patients how to adjust insulin doses relative to amount of carbohydrate they’re consuming.
DKA is more common in which form of diabetes?
Type 1 Diabetes
What is the most common management error leading to DKA?
Patients reducing/omitting insulin due to being unable to eat (nausea/vomiting).
Insulin should never be stopped, only adjusted.
Describe the pathophysiology of DKA (3)
Body responds as if were hypoglycaemic, stimulating ketogenesis
Uncontrolled peripheral lipolysis causes increase in free fatty acids > increases in Acetyl CoA results in excess ketone production.
Ketones are strong acids, so lower the pH of the blood, leading to metabolic acidosis.
Increased acidity of the blood impairs the ability of haemoglobin to bind to oxygen.
Give 4 symptoms of DKA
Breath/Urine smells like pear drops
Polyuria, Polydipsia, Dehydration (leading to AKI)
Vomiting/Severe weight loss
Hyperventilation/Breathlessness (Kussmaul’s respiration)
Define Kussmaul’s respiration. What complication of diabetes is it associated with? (2)
Associated with DKA
Describes paradoxical rise in JVP on inspiration or failure for appropriate fall of JVP with inspiration.
Give 3 diagnostic factors for DKA
Hyperglycaemia (blood glucose >11mmol/L)
Raised plasma ketones (Urine >2+ or >3mmol/L in blood)
Metabolic acidosis (plasma bicarbonate <15mmol/L, Blood pH <7.3)
What other features may be present on a blood test in patients with DKA?
Hyperkalaemia (acidosis promotes potassium efflux from cells) (Insulin can promote potassium influx into cells vis Na/H antiporter - sodium influx stimulates Na/K ATPase)
Raised urea and creatinine (renal failure)
How is DKA managed? (3)
Fluids - 0.9% Sodium Chloride +/- Potassium Chloride
Insulin - (IV infusion at 0.1unit/Kg/hour) (once blood glucose is <14mmol/L, 10% dextrose should be started in addition to 0.9% sodium chloride).
Long acting insulin should be continues, short-acting insulin should be stopped
How is DKA resolution defined? (3)
DKA resolution defined as;
pH >7.3 AND blood ketones <0.6mmol/L AND bicarbonate >15mmol/L
Give 5 complications of DKA
Gastric stasis
Thromboembolism (hyperglycaemia causes hyperviscosity -thicker blood)
Cardiac arrhythmias (due to hyper/hypokalaemia)
Acute respiratory distress syndrome
Acute kidney injury
Name 1 common trigger for DKA and how is causes DKA.
Infection
Increases epinephrine release > increases glucagon levels > results in gluconeogenesis and glycogenolysis > hyperglycaemia
Give 1 important complication of fluid resuscitation in DKA (especially in young patients). How may this present and why does this occur?
Cerebal oedema
Presents as; Low GCS, Incontinence, vomiting, resp symptoms; grunting, apnoea, tachypnoea
When fluids are given too quickly, the sudden drop in blood osmolarity can lead water to move into cerebral tissue, causing oedema
Describe type 2 diabetes
Describes diabetes mellitus forming from a combination of insulin resistance and less severe insulin deficiency.
Describe the epidemiology of type 2 diabetes (4)
Age - Patients tend to be > 40
Fitness - Patients tend to be overweight/obese
Ethnicity - Tends to be more prevelent in South Asian, African and Caribbean
Sex - More common in males
Give 4 risk factors for type 2 diabetes
Obesity/lack of exercise/calorie alcohol excess
Increasing age
Family history
Low birth weight (impairs beta cell development and function)
Describe the pathophysiology of type 2 diabetes
Insulin resistance likely occurs due to a defect in the translocation of GLUT4 to the membrane.
Established T2DM leads to hypersecretion of insulin by depleted beta cells. Resulting in high circulating levels of insulin.
Insulin blood levels increase due to increased glucose production from the liver (due to inadequate suppression of gluconeogenesis) and reduced glucose uptake by peripheral tissues (insulin resistance).
Why don’t type 2 diabetics tend to develop DKA?
As even a small amount of insulin can halt the breakdown of fat and muscle into ketones.
Define 2 states of pre-diabetes
Impaired glucose tolerance (IGT) - When blood glucose levels are elevated but they’re not high enough to be classified as diabetes
Impaired Fasting Glucose (IFG) - When blood glucose levels are elevated in a fasting state but they’re not high enough to be classified as diabetes.
Describe 4 macrovascular complications of Type 2 diabetes
Myocardial infarction (4x more common)
Stroke (2x more common)
Atherosclerosis (can lead to stroke, IHD or PVD)
Peripheral Vascular Disease (can lead to amputation)
Diagnostically define Impaired Glucose Tolerance (IGT) (2)
Fasting plasma glucose - <7mmol/L
Oral glucose tolerance test - >7mmol/L but <11mmol/L
Describe 4 symptoms of peripheral vascular disease secondary to type 2 diabetes
Diminished or absent pedal pulses
Coolness of feet
Poor skin and nails
Absence of hair on feet and legs
Diagnostically define Impaired Fasting Glucose (IFG)
Fasting Plasma Glucose - >6.1mmol/L but <7mmol/L
How can peripheral vascular disease be detected?
Detected via doppler ultrasound
How is type 2 diabetes diagnosed? (3)
Fasting plasma glucose >7mmol/L
Random plasma glucose >11.1mmol/L
HbA1c >48mmol/mol (diagnostic)
(must be fulfilled on 2 separate occasions if asymptomatic)
When may HbA1c not be used for diagnosis of Type 2 diabetes? (8)
Increase in HbA1c can be caused by increased red cell turnover, occurring in;
Haemoglobinopathies
Haemolytic anaemia
Untreated iron deficiency anaemia
Gestational diabetes
Children
HIV
CKD
Corticosteroid use
Describe the initial management of Type 2 Diabetes (3)
Assess cardiovascular risk (QRISK >10%)
If QRISK <10% - Metformin
If QRISK >10% or Pt has CVD, or Pt has chronic heart failure - Metformin + SGLT-2 inhibitor (Empagliflozin/Dapagliflozin)
*SGLT-2 inhibitors should be started at any point if patient develops CVD)
Describe risk factor management patient Type 2 diabetes (4)
Lifestyle and dietary changes
Blood pressure control - Ramipril (ACEi) or ARB (in Afro-Caribbean)
Hyperlipidaemia control - Statins (Atorvastatin if QRISK >10%)
Obesity control - Orlistat
When metformin be contraindicated? Why? (3)
Heart failure
Liver disease
Renal disease
Can induce lactic acidosis
Give 4 side effects of metformin
Gastrointestinal upset;
Anorexia
Diarrhoea
Nausea
Abdominal pain
What should be given as an initial management of type 2 diabetes if metformin is contraindicated? (2)
If patient has CVD disease/risk - SGLT-2 monotherapy
If patient does not have CVD disease/risk - DPP-4 inhibitor or pioglitazone or a sulfonylurea
Describe the treatment ladder for Type 2 diabetes (3)
1st line (monotherapy) - Metformin (+/- SGLT-2 inhibitor - depending on CVD risk)
2nd line (dual therapy) - Add; DPP-4 inhibitor OR Pioglitazone OR sulfonylurea OR SGLT-2 inhibitor
3rd line;
- Metformin + DPP-4 inhibitor + sulfonylurea
- Metformin + Pioglitazone + Sulfonylurea
- Metformin + (Pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGL-2 inhibitor
- Insulin based treatment
What is the 4th line treatment for type 2 diabetes?
Glucagon-like peptide (GLP analogues) - Exenatide + Liraglutide
Describe the HbA1c targets for patients on lifestyle or single drug treatments of Type 2 diabetes
Lifestyle - 48mmol/mol
Lifestyle + metformin - 48mmol/mol
Lifestyle + Sulfonylurea (can cause hypoglycaemia) - 53mmol/mol
What is the HbA1c target for type 2 diabetic already on 1 drug but HbA1c has risen to 58mmol/mol?
53mmol/mol
Describe the MOA of metformin (2)
Suppresses gluconeogenesis and glycogenolysis in liver
Increases cells’ sensitivity to insulin
Name and describe MOA of DPP4 inhibitors
Sitagliptin (gliptins)
Dipeptidyl peptidase 4 inhibitors. DPP4 usually breaks down incretin. Incretin stimulates insulin release facilitating decrease in blood glucose levels.
What can DPP4-inhibitors (gliptins) increase the risk of?
Pancreatitis
Name and describe the moa of sulfonylurea
Gliclazide
Stimulates insulin secretion from pancreatic beta cells by binding and blocking K+ channels > stimulates influx of calcium into beta cells > stimulates exocytosis of vesicles containing insulin.
When should sulfonylureas not be used?
In obese patients as can cause weight cain and fluid retention.
Can also cause hypoglycaemia if overused.
Name and describe MOA of SGLT-2 inhibitors
Empagliflozin and Dapagliflozin
Selective sodium glucose co-transporter 2 inhibitor
Blocks glucose reabsorption in the proximal tubule, promoting excretion of glucose in urine
Give 3 side effects of SGLT-2 inhibitors (Empagliflozin/Dapagliflozin)
DKA, Hypoglycaemia, Increased risk of Infection
Describe the MOA of poiglitazone
Increases cellular insulin sensitivity
Give 3 complications of pioglitazone
Increases risk of heart failure, bladder cancer and bone fractures
In who should pioglitazone be avoided? (4)
In patients with history of;
Bladder cancer
Heart Failure
Hepatic Impairment
DKA
How can diabetic nephropathy be diagnosed?
Urine Albimin:Creatinine ratio >3 indicated microalbuminuria
How is diabetic nephropathy treated? (2)
ACEi/ARBs (ramipril/candesartan)
Avoid metformin (contraindicated in renal disease)
Name symptoms of diabetic neuropathy (2-7)
Somatic symptoms;
Pain (worse at night)
Numbness (glove and stocking distribution - hands and feet)
Pareaesthesia
Autonomic symptoms;
Postural hypotension
Gastroparesis
Diarrhoea, constipation, incontinence
Erectile dysfunction
Describe a life threatening emergency associated with uncontrolled type 2 diabetes (3)
Hyperosmolar Hypeglycaemic State.
Characterised by marked hyperglycaemia, hyperosmolality and mild/no ketosis.
Important to distinguish from DKA as insulin therapy (Mx of DKA) can produce adverse effects of HHS
How is diabetic neuropathy managed?
1st line - Amitriptyline, Duloxetine, Gabapentin or Pregabalin
Tramadol can be used as a ‘rescue therapy’ for exacerbations of neuropathic pain
Give 3 risk factors for hyperosmolar hyperglycaemic state
Infection (most common) (particularly pneumonia)
Consumption of glucose rich fluids
Concurrent medications; thiazide diuretics or steroids
In who should amitryptiline be avoided?
In those with urinary retention (i.e BPH)
AmiDRIPtiline
Describe the pathophysiology of Hyperosmolar Hyperglycaemic State
Insulin levels decrease > Hepatic ketogenesis is inhibited but hepatic gluconeogenesis still occurs > Hyperglucaemia > osmotic diuresis > Loss of sodium and potassium > volume depletion and raised serum osmolairy > Hyperviscosity
Describe the clinical presentation of Hyperosmolar Hyperglycaemic State (4)
Osmotic symptoms (polyuria, polydipsia, weight loss)
Severe dehydration
Decreased level of consciousness
Stupor (near unconsciousness) or coma (rare)
What tests may be conducted to investigate ? Hyperosmolar Hyperglucaemic State (5)
Blood glucose - >30mmol/L, no ketones or acidosis (pH >7.3, bicarbonate >15mmol/L)
Hyperosmolality - >320mmol/Kg
Urine dipstick - Heavy glycosuria)
Hypovolemia
Hyperkalaemia/hypokalaemia
How is hyperosmolar hyperglycaemic state managed?
Slow rehydration - 0.9% saline +/- electrolyte replacement over 48 hours
Insulin - only if blood glucose is NOT falling by 5mmol/L following rehydration OR if NO ketonaemia present
Low Molecular Weight Heparin - Enoxaparin
(reduces risk of thromboembolism, stroke, MI)
What is the function of the thyroid?
Controls metabolism, growth and development.
What 3 hormones are produced by the thyroid?
T3 - Most active
T4 (thyroxine) - Less active but more abundant
Calcitonin (produced by parafollicular cells)
What molecule and process is required for the synthesis of thyroid hormones?
Iodine
Iodination of tyrosine molecules AND combination of two tyrosine residues.
Describe the Hypothalamic Pituitary Thyroid Axis
HPT axis regulates thyroid hormone synthesis
Neurones in the paraventricular nucleus of the hypothalamus release Thyrotropin Releasing Hormone (TRH).
TRH stimulates release of Thyroid Stimulating Hormone (THS) from the anterior pituitary.
TSH travels to thyroid gland and stimulates release of T3 and T4.
T3 and T4 negatively feedback to TSH and TRH.
From where is Thyotropin Releasing Hormone released?
Paraventricular Nucleus of the Hypothalamus
From where is Thyroid Stimulating Hormone produced?
Anterior pituitary
Describe the Wolff-Chiakoff effect. When is this useful clinically?
Describes an autoregulatory phenomenon in which thyroid hormone synthesis is inhibited irrespective of serum TSH levels, when excess iodine is ingested.
Useful clinically as pharmaceutical doses of iodine may be used to acutely reduce thyroid activity.
Name 3 types of thyroid disorders
Hyperthyroidism - Graves’ Disease (overactive thyroid)
Hypothyroidism - Hashimoto’s thyroiditis/Iodine deficiency (underactive thyroid)
Thyrotoxicosis (excessive amount of thyroid hormone in in the body)
Describe 2 types of goitre formation and describe when they’re seen?
Diffuse (Entire thyroid gland swells, is smooth to touch)
Associated with; Iodine deficiency, Graves’, Hashimotos, De Quervain’s
Nodular (lumpy - solitary or multinodular)
Associated with: adenoma/cyst, carcionma
What hormone is the basis of screening for possible thyroid disease?
TSH
What will circulating levels of TSH, T4 and T3 look like in primary hyperthyroidism?
Low TSH
High T4
High T3
What will circulating TSH, T3 and T4 levels look like in hypothyroidism?
High TSH
Low T3
Low T4
If TSH is raised, T3 is low and T4 is raised, what is the likely diagnoses? Why?
Deiodinase deficiency or euthyroid hypothyroxinaemia
Because T4 is converted into T3 by deiodinases. If these are deficient then T3 is unable to be generated.
Thyroid function tests - Name 3 antibodies that are useful for diagnosing autoimmune thyroid disease.
Anti-TPO antibodies (Graves’/Hashimoto’s)
Antithyroglobulin antibodies (Graves’/Hashimoto’s/Cancer)
TSH receptor antibodies (Graves’)
Thyroid function tests - What imaging tool is used to investigate thyroid nodules?
Ultrasound (can also be used for guided biopsy)
Thyroid function tests - Describe the use and purpose of a radioisotope scan
Used to investigate hyperthyroidism and thyroid cancers, providing functional information about the thyroid.
Radioactive iodine is given orally/IV. This is taken up by the thyroid.
The more active the thyroid cells, the faster the radioactive iodine will be taken up.
(e.g Graves will show diffuse uptake of radioactive iodine. Toxic multi-nodular goitre will show focal high uptake)
Define primary hyperthyroidism
Describes pathology of the thyroid itself, causing it to produce too much thyroid hormone
Define secondary hyperthyroidism
Occurs when the thyroid is producing too much thyroid hormone due to overstimulation from thyroid stimulating hormone (TSH).
May rise due to an issue with the pituitary or hypothalamus.
Give 5 causes of hyperthyroidism
Graves’ disease
Toxic Multinodular goitre
Solitary toxic adenoma/nodule
Amiodarone
Sub acute de Quervain’s thyroiditis
Describe Graves’ disease
Most common form of hyperthyroidism.
Graves’ disease describes an autoimmune disease characterised by the production of Thyroid Stimulating Immunoglobin (igG) from b lymphocytes.
Thyroid Stimulating Immunoglobin mimics TSH, binds to and activates TSH receptors on the thyroid cell membrane, stimulating synthesis of T3 and T4.
Give 5 risk factors for Graves’ disease
Female (biggest risk factor - common post-partum)
Genetic association (HLA-B8, DR2 and DR3)
Infection - E.coli contain TSH binding sites.
High iodine intake
Autoimmune disease (vitiligo, addisons, pernicious anaemia, myasthenia gravis, Type 1 diabetes)
Name 5 autoimmune diseases associated with Grave’s disease
Vitiligo
Addison’s disease
Pernicious anaemia
Myasthenia gravis
Type 1 diabetes
Give 5 clinical features of Graves’ disease
Sweating, weight loss, irritability
Palpitations/tachycardia/cardiac flow murmur
Diffuse (smooth) goitre
Heat intolerance
Graves orbitopathy (only occurs in Graves’)
How may Graves’ orbitopathy present? (3)
Presents in 25% of Graves’ patients
Results in retro-orbital inflammation and swelling of the extraocular muscles
May present as;
Upper eyelid retraction
Exophthalmos (protruding eye)
Optic neuropathy
Give 2 rare but distinct clinical signs of Graves’ disease
Pretibial myxoedema - Arises from excess hyaluronic acid leading to deposits of mucin under the skin. Presents as swelling and lumpiness in the lower legs (may be red)
Acropachy - Finger clubbing with erosion of the distal phalanges
What will thyroid function tests show in a patient with Graves’ disease?
Free TSH - Low
Serum T4/T3 - High
TSH receptor antibodies - Positive (highly specific)
What test can be used to identify Graves Orbitopathy?
MRI or CT
How is Graves’ disease initially managed?
Symptom control;
Beta blockers - Propranolol
Hydrocortisone (for Graves’ dermopathy)
IV Methylprednisolone (for Graves’ orbitopathy)
Antithyroid drugs;
First line - Carbimazole (continued for 12-18 months)
Second line - Propylthiouracil (used in pregnancy as Carbimazole is teratogenic)
If Graves’ patient relapses following Anti-Thyroid Drug treatment, what treatment is offered?
1st line - Radioiodine treatment
2nd line - Thyroidectomy
Give 1 complication of radioiodine therapy
Can lead to hypothyroidism resulting in patient requiring thyroxine replacement therapy (levothyroxine)
What is the major complication of Carbimazole?
Agranulocytosis (increases risk of sepsis)
Give 3 possible consequences of thyroidectomy
Can risk damaging the recurrent laryngeal nerve
Can cause parathyroidism
Patients become hypothyroid so require life-long thyroid replacement therapy.
Name and describe 2 treatment strategies for hyperthyroidism
Titration Regimen (12-18 months) - Dose of drug is reduced (every 1-2 months) with the aim of keeping the patient on the lowest dose required for normal thyroid function.
Block and replace - Give high dose carbimazole to stop thyroid producing T3/T4. When T3/T4 levels return to normal range, give levothyroxine replacement.
What is the MOA of Carbimazole?
Inhibits TPO from coupling and iodinating tyrosine residues.
In whom is Carbimazole contraindicated?
In pregnancy as it is teratogenic
Describe subclinical hyperthyroidism (2)
Describes a condition where there is low TSH levels but normal T3 and T4.
Most causes are iatrogenic, especially due to over treatment with levothyroxine (T4)